Home > Journals > Minerva Biotechnology and Biomolecular Research > Past Issues > Minerva Biotechnology and Biomolecular Research 2021 June;33(2) > Minerva Biotechnology and Biomolecular Research 2021 June;33(2):53-64

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as
Share

 

REVIEW  BIOTECHNOLOGICAL AND PHARMACOLOGICAL DEVELOPMENTS IN THE MODIFICATION OF CHRONIC INFLAMMATION-INDUCED DISEASES 

Minerva Biotechnology and Biomolecular Research 2021 June;33(2):53-64

DOI: 10.23736/S2724-542X.21.02762-0

Copyright © 2021 EDIZIONI MINERVA MEDICA

language: English

Application features of biological therapy in patients with autoimmune diseases

Natalia KOZAK 1 , Olena BARABANCHYK 2, Mariia SOBCHENKO 1, Nataliia MOLOCHEK 2, Nadiia DOLGAIA 2, Yuri PENCHUK 2, Galyna MYKHALCHYSHYN 1

1 Bogomolets National Medical University, Kyiv, Ukraine; 2 Educational and Scientific Center, Institute of Biology and Medicine, Taras Shevchenko National University of Kyiv, Kyiv, Ukraine



The article presents modern data on the use of a wide range of immunobiological drugs in various autoimmune rheumatic diseases. The results of numerous clinical studies are presented regarding the effectiveness and safety of the latest promising drugs and describe the features of expediency and sequence of appointment, dosage, and duration of use of registered drugs in specific nosologies and various clinical forms of rheumatic diseases.


KEY WORDS: Therapeutics; Rheumatic diseases; Clinical trial

top of page